•  
  •  
 

Document Type

Original Article

Abstract

Background: Anemia is multifactorial in ESRD cases. It has been shown to be primarily caused by insufficient erythropoietin (EPO) synthesis combined with erythropoietin resistance and an increased erythropoietin demand. EPO stimulates the production of red blood cells in the bone marrow. Therefore, recombinant human EPO therapy (rHuEPO) is the primary medication for ESRD-associated anemia. Objective: Determine the predictive value of anti-EPO levels in the monitoring of erythropoietin resistance in those receiving hemodialysis. Patients and methods: This Cross-Sectional Study was conducted in the hemodialysis facilities of the Department of Internal Medicine at Al-Azhar University Hospital for Boys in Cairo. During a six-month period, ninety subjects underwent regular hemodialysis. Patients were separated into two categories; the first group received rhuEPO therapy, while the second group did not. Results: There was a statistically significant difference among our research population & the laboratory parameters anti-Erythropoietin antibodies, HB, HCT and EPO.IU (week). There was no statistically significant difference among the sexes and Comorbidities in our research population. Conclusion: Anti-EPO antibodies are generally prevalent among people on dialysis receiving rhuEPO. Resistance to rhuEPO medication can increase the risk of subsequent adverse outcomes in CKD cases. There were negative correlations among anti-EPO titre and laboratory data of CKD cases, including HB, HCT and MCHC as well as the dose of rHuEPO administered.

Keywords

Soluble Anti- Erythropoietin; Erythropoietin Resistance; Hemodialysis.

Subject Area

General Medicine

Download

Share

COinS